Loading...

John O'quigley

TitleEmeritus Professor
InstitutionUniversity of California San Diego
DepartmentMathematics
Address9500 Gilman Drive #0112
La Jolla CA 92093
vCardDownload vCard

    Collapse Research 
    Collapse Research Activities and Funding
    NEW DESIGNS FOR DOSE FINDINGS STUDIES IN CANCER
    NIH/NCI R01CA077404Apr 1, 1998 - Mar 31, 2002
    Role: Principal Investigator

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
    List All   |   Timeline
    1. O'Quigley J. Faulty BRCA1, BRCA2 genes: how poor is the prognosis? Ann Epidemiol. 2017 10; 27(10):672-676. PMID: 29017890.
      View in: PubMed
    2. Yap C, Billingham LJ, Cheung YK, Craddock C, O'Quigley J. Dose Transition Pathways: The Missing Link Between Complex Dose-Finding Designs and Simple Decision-Making. Clin Cancer Res. 2017 Dec 15; 23(24):7440-7447. PMID: 28733440.
      View in: PubMed
    3. Flandre P, Deutsch R, O'Quigley J. Accuracy of predictive ability measures for survival models. Stat Med. 2017 Sep 10; 36(20):3171-3180. PMID: 28589544.
      View in: PubMed
    4. Iasonos A, O'Quigley J. Early phase dose finding methodology. Stat Med. 2017 01 30; 36(2):201-203. PMID: 27921353.
      View in: PubMed
    5. Chauvel C, O'Quigley J. Survival model construction guided by fit and predictive strength. Biometrics. 2017 06; 73(2):483-494. PMID: 27706799.
      View in: PubMed
    6. Iasonos A, O'Quigley J. Integrating the escalation and dose expansion studies into a unified Phase I clinical trial. Contemp Clin Trials. 2016 09; 50:124-34. PMID: 27393122.
      View in: PubMed
    7. Iasonos A, Wages NA, Conaway MR, Cheung K, Yuan Y, O'Quigley J. Dimension of model parameter space and operating characteristics in adaptive dose-finding studies. Stat Med. 2016 09 20; 35(21):3760-75. PMID: 27090197.
      View in: PubMed
    8. Iasonos A, O'Quigley J. Sequential monitoring of Phase I dose expansion cohorts. Stat Med. 2017 01 30; 36(2):204-214. PMID: 26854196.
      View in: PubMed
    9. Iasonos A, O'Quigley J. Clinical trials: Early phase clinical trials-are dose expansion cohorts needed? Nat Rev Clin Oncol. 2015 Nov; 12(11):626-8. PMID: 26441082; PMCID: PMC4758199.
    10. Salter A, O'Quigley J, Cutter GR, Aban IB. Two-group time-to-event continual reassessment method using likelihood estimation. Contemp Clin Trials. 2015 Nov; 45(Pt B):340-345. PMID: 26409251.
      View in: PubMed
    11. Iasonos A, O'Quigley J. Adaptive dose-finding studies: a review of model-guided phase I clinical trials. J Clin Oncol. 2014 Aug 10; 32(23):2505-11. PMID: 24982451; PMCID: PMC4121508.
    12. Wages NA, Conaway MR, O'Quigley J. Comments on 'A dose-finding approach based on shrunken predictive probability for combinations of two agents in phase I trials' by Akihiro Hirakawa, Chikuma Hamada, and Shigeyuki Matsui. Stat Med. 2014 May 30; 33(12):2156-8. PMID: 24797319.
      View in: PubMed
    13. O'Quigley J, Iasonos A. Bridging Solutions in Dose Finding Problems. Stat Biopharm Res. 2014 May 01; 6(2):185-197. PMID: 25071878.
      View in: PubMed
    14. Iasonos A, O'Quigley J. Design considerations for dose-expansion cohorts in phase I trials. J Clin Oncol. 2013 Nov 01; 31(31):4014-21. PMID: 24101039; PMCID: PMC4979131.
    15. Wages NA, Conaway MR, O'Quigley J. Performance of two-stage continual reassessment method relative to an optimal benchmark. Clin Trials. 2013; 10(6):862-75. PMID: 24085776; PMCID: PMC4361948.
    16. Wages NA, O'Quigley J, Conaway MR. Phase I design for completely or partially ordered treatment schedules. Stat Med. 2014 Feb 20; 33(4):569-79. PMID: 24114957; PMCID: PMC3947103.
    17. Iasonos A, O'Quigley J. Interplay of priors and skeletons in two-stage continual reassessment method. Stat Med. 2012 Dec 30; 31(30):4321-36. PMID: 22893483; PMCID: PMC3538840.
    18. Chen J, Liu L, Johnson BA, O'Quigley J. Penalized likelihood estimation for semiparametric mixed models, with?application to alcohol treatment research. Stat Med. 2013 Jan 30; 32(2):335-46. PMID: 22833388.
      View in: PubMed
    19. Iasonos A, Gounder M, Spriggs DR, Gerecitano JF, Hyman DM, Zohar S, O'Quigley J. The impact of non-drug-related toxicities on the estimation of the maximum tolerated dose in phase I trials. Clin Cancer Res. 2012 Oct 01; 18(19):5179-87. PMID: 22825582; PMCID: PMC3463734.
    20. Wages NA, Conaway MR, O'Quigley J. Using the time-to-event continual reassessment method in the presence of partial orders. Stat Med. 2013 Jan 15; 32(1):131-41. PMID: 22806898; PMCID: PMC3521068.
    21. Iasonos A, Zohar S, O'Quigley J. Incorporating lower grade toxicity information into dose finding designs. Clin Trials. 2011 Aug; 8(4):370-9. PMID: 21835856; PMCID: PMC3293181.
    22. O'Quigley J, Flandre P. Discussion by O'Quigley and Flandre. Biometrics. 2012 Mar; 68(1):242-4; discussion 245-7. PMID: 21668900.
      View in: PubMed
    23. Wages NA, Conaway MR, O'Quigley J. Dose-finding design for multi-drug combinations. Clin Trials. 2011 Aug; 8(4):380-9. PMID: 21652689; PMCID: PMC3485079.
    24. Wages NA, Conaway MR, O'Quigley J. Continual reassessment method for partial ordering. Biometrics. 2011 Dec; 67(4):1555-63. PMID: 21361888; PMCID: PMC3141101.
    25. O'Quigley J, Conaway M. Extended model-based designs for more complex dose-finding studies. Stat Med. 2011 Jul 30; 30(17):2062-9. PMID: 21351287; PMCID: PMC3480175.
    26. Iasonos A, O'Quigley J. Continual reassessment and related designs in dose-finding studies. Stat Med. 2011 Jul 30; 30(17):2057-61. PMID: 21351292; PMCID: PMC3740341.
    27. Zohar S, Katsahian S, O'Quigley J. An approach to meta-analysis of dose-finding studies. Stat Med. 2011 Jul 30; 30(17):2109-16. PMID: 21344473.
      View in: PubMed
    28. O'Quigley J. Dynamic equilibrium of reconstituting hematopoietic stem cell populations. J Bioinform Comput Biol. 2010 Dec; 8(6):1041-51. PMID: 21121026.
      View in: PubMed
    29. O'Quigley J, Zohar S. Retrospective robustness of the continual reassessment method. J Biopharm Stat. 2010 Sep; 20(5):1013-25. PMID: 20721788.
      View in: PubMed
    30. O'Quigley J, Hughes MD, Fenton T, Pei L. Dynamic calibration of pharmacokinetic parameters in dose-finding studies. Biostatistics. 2010 Jul; 11(3):537-45. PMID: 20203258; PMCID: PMC2883303.
    31. O'Quigley J, Conaway M. Continual Reassessment and Related Dose-Finding Designs. Stat Sci. 2010; 25(2):202-216. PMID: 21731191.
      View in: PubMed
    32. O'Quigley J. Commentary on 'Designs for dose-escalation trials with quantitative responses'. Stat Med. 2009 Dec 30; 28(30):3745-50; discussion 3759-60. PMID: 19967752.
      View in: PubMed
    33. Zohar S, O'Quigley J. Re: Dose escalation methods in phase I cancer clinical trials. J Natl Cancer Inst. 2009 Dec 16; 101(24):1732-3; author reply 1733-5. PMID: 19893006.
      View in: PubMed
    34. Zohar S, O'Quigley J. Sensitivity of dose-finding studies to observation errors. Contemp Clin Trials. 2009 Nov; 30(6):523-30. PMID: 19580886.
      View in: PubMed
    35. Liu L, Ma JZ, O'Quigley J. Joint analysis of multi-level repeated measures data and survival: an application to the end stage renal disease (ESRD) data. Stat Med. 2008 Nov 29; 27(27):5679-91. PMID: 18693300.
      View in: PubMed
    36. Shu J, O'Quigley J. Dose-escalation designs in oncology: ADEPT and the CRM. Stat Med. 2008 Nov 20; 27(26):5345-53; discussion 5354-5. PMID: 18752259.
      View in: PubMed
    37. Liu L, Huang X, O'Quigley J. Analysis of longitudinal data in the presence of informative observational times and a dependent terminal event, with application to medical cost data. Biometrics. 2008 Sep; 64(3):950-8. PMID: 18162110.
      View in: PubMed
    38. Flandre P, O'Quigley J. Predictive strength of Jonckheere's test for trend: an application to genotypic scores in HIV infection. Stat Med. 2007 Oct 30; 26(24):4441-54. PMID: 17397042.
      View in: PubMed
    39. Zohar S, O'Quigley J. Optimal designs for estimating the most successful dose. Stat Med. 2006 Dec 30; 25(24):4311-20. PMID: 16969893.
      View in: PubMed
    40. Zohar S, O'Quigley J. Identifying the most successful dose (MSD) in dose-finding studies in cancer. Pharm Stat. 2006 Jul-Sep; 5(3):187-99. PMID: 17080752.
      View in: PubMed
    41. O'Quigley J, Flandre P. Quantification of the prentice criteria for surrogate endpoints. Biometrics. 2006 Mar; 62(1):297-300. PMID: 16542258.
      View in: PubMed
    42. O'Quigley J. Retrospective analysis of sequential dose-finding designs. Biometrics. 2005 Sep; 61(3):749-56. PMID: 16135026.
      View in: PubMed
    43. O'Quigley J, Xu R, Stare J. Explained randomness in proportional hazards models. Stat Med. 2005 Feb 15; 24(3):479-89. PMID: 15532086.
      View in: PubMed
    44. O'Quigley J, Natarajan L. Erosion of regression effect in a survival study. Biometrics. 2004 Jun; 60(2):344-51. PMID: 15180659.
      View in: PubMed
    45. Natarajan L, O'Quigley J. Interval estimates of the probability of toxicity at the maximum tolerated dose for small samples. Stat Med. 2003 Jun 15; 22(11):1829-36. PMID: 12754718.
      View in: PubMed
    46. O'Quigley J, Paoletti X. Continual reassessment method for ordered groups. Biometrics. 2003 Jun; 59(2):430-40. PMID: 12926728.
      View in: PubMed
    47. O'Quigley J, Stare J. Proportional hazards models with frailties and random effects. Stat Med. 2002 Nov 15; 21(21):3219-33. PMID: 12375300.
      View in: PubMed
    48. O'Quigley J. Curve-free and model-based continual reassessment method designs. Biometrics. 2002 Mar; 58(1):245-9. PMID: 11890323.
      View in: PubMed
    49. O'Quigley J, Paoletti X, Maccario J. Non-parametric optimal design in dose finding studies. Biostatistics. 2002 Mar; 3(1):51-6. PMID: 12933623.
      View in: PubMed
    50. O'Quigley J. Continual reassessment designs with early termination. Biostatistics. 2002 Mar; 3(1):87-99. PMID: 12933626.
      View in: PubMed
    John's Networks
    Concepts
    Derived automatically from this person's publications.
    _
    Co-Authors
    People in Profiles who have published with this person.
    _
    Related Authors
    People who share related concepts with this person.
    _